Oct 30 (Reuters) - Corcept Therapeutics Q3 revenue USD 182.546 million vs. IBES estimate USD 172 million.
Q3 net income USD 47.213 million vs. IBES estimate USD 32.4 million
Q3 cash & investments USD 547.6 million
outlook FY revenue USD 675-700 million
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.